Verrica Pharmaceuticals Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Verrica Pharmaceuticals Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$16For every $100 of sales, $16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $0 from others' credit three years earlier.
Less money tied up than 67% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$25Sales grew 294% in 3 years; of every extra $100 of sales, $25 became extra profit.
Higher than 55% of Healthcare companies in United States.
Asset Productivity Ratio
+294% / +5%In 3 years sales changed by +294% while total assets changed by +5%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-23.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+43%Cash, after subtracting all debt, equals 43% of its market value (net cash).
Higher than 75% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Verrica Pharmaceuticals Inc. made a loss over the last year. Verrica Pharmaceuticals Inc. owes $0.88 for every $1 it owns. Verrica Pharmaceuticals Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossVerrica Pharmaceuticals Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
15.28The share price is 15.28 times Verrica Pharmaceuticals Inc.'s book value per share, higher than 91% of Healthcare companies in United States.
Market cap
$66 MThe total market value of all of Verrica Pharmaceuticals Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$4 MWhat Verrica Pharmaceuticals Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.25Net worth divided by the number of shares. The share price of $3.83 is 15.3 times this, which is the P/B above.
Owes vs Owns
0.88×Verrica Pharmaceuticals Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Dividend yield
NoneVerrica Pharmaceuticals Inc. does not currently pay a dividend.
Revenue growth
+370%Revenue rose 370% in the year to Dec 2025, and grew 58% a year on average over 3 years.
Profit growth
LossVerrica Pharmaceuticals Inc. made a loss in each of the last two years.
Profit margin
-50.3%Verrica Pharmaceuticals Inc. lost $50 for every $100 of revenue.
Interest cover
Not coveredVerrica Pharmaceuticals Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashVerrica Pharmaceuticals Inc. held $29 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Verrica Pharmaceuticals Inc.: $66 M ÷ $4 M (30 Jun 2026) = 15.3.
How much does Verrica Pharmaceuticals Inc. owe compared with what it owns?
Verrica Pharmaceuticals Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Does Verrica Pharmaceuticals Inc. pay a dividend?
No. Verrica Pharmaceuticals Inc. does not currently pay a dividend.
Is Verrica Pharmaceuticals Inc.'s revenue growing?
Revenue rose 370% in the year to Dec 2025, and grew 58% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.